Alphamab Oncology Sustainability Reports
Alphamab Oncology is a clinical-stage biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative therapeutics for cancer treatment. Its portfolio primarily targets bispecific antibodies and antibody-drug conjugates (ADCs) to address unmet oncology clinical needs globally.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
ISIN: KYG0330A1013
21 reports from 2019 to 2025